TY - JOUR
T1 - Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life
AU - SANI Network (Severe Asthma Network Italy)
AU - Bagnasco, Diego
AU - Povero, Massimiliano
AU - Pradelli, Lorenzo
AU - Brussino, Luisa
AU - Rolla, Giovanni
AU - Caminati, Marco
AU - Menzella, Francesco
AU - Heffler, Enrico
AU - Canonica, Giorgio Walter
AU - Paggiaro, Pierluigi
AU - Senna, Gianenrico
AU - Milanese, Manlio
AU - Lombardi, Carlo
AU - Bucca, Caterina
AU - Manfredi, Andrea
AU - Canevari, Rikki Frank
AU - Passalacqua, Giovanni
AU - Guarnieri, Gabriella
AU - Patella, Vincenzo
AU - Maria Pia, Foschino Barbaro
AU - Carpagnano, Elisiana
AU - Colle, Anna del
AU - Scioscia, Giulia
AU - Gerolamo, Pelaia
AU - Puggioni, Francesca
AU - Racca, Francesca
AU - Galeone, Carla
AU - Ruggiero, Patrizia
AU - Colombo, Gisella
AU - Blasi, Francesco
AU - D'Adda, Alice
AU - Parente, Roberta
AU - Corsico, Angelo Guido
AU - Grosso, Amelia
AU - Spanevello, Antonio
AU - Pignatti, Patrizia
AU - Cherubino, Francesca
AU - Visca, Dina
AU - Aletti, Eleonora
AU - Santus, Pierachille
AU - Barlassina, Roberta
AU - Aruanno, Arianna
AU - Marchi, Maria Rita
AU - Maggi, Enrico
AU - Richeldi, Luca
AU - Bonini, Matteo
AU - Carli, Giulia
AU - Montuschi, Paolo
AU - Santini, Giuseppe
AU - Tarsia, Paolo
N1 - Funding Information:
Lorenzo Pradelli is co-owner and employee of AdRes, which has received project funding from GSK. Massimiliano Povero is employee of AdRes, which has received project funding from GSK. None for other authors. SANI is supported by Unrestricted Grants from AstraZeneca, Glaxo Smith Kline, Novartis & Sanofi Genzyme.
Publisher Copyright:
© 2021 The Authors
PY - 2021/2
Y1 - 2021/2
N2 - Background and aims: Severe asthma is burdened by frequent exacerbations and use of oral corticosteroids (OCS) which worsen patients’ health and increase healthcare spending. Aim of this study was to assess the clinical and economic effect of adding mepolizumab (MEP) for the treatment of these patients. Methods: Patients >18 years old, referred to 8 asthma clinics, starting MEP between May 2017 and December 2018, were enrolled and followed-up for 12 months. Information in the 12 months before mepolizumab were collected retrospectively. The evaluation parameters included: OCS use, number of exacerbations/hospitalizations, concomitant therapies, comorbidity, and annual number of working days lost due to the disease. The primary objective was to compare the annual total cost per patient pre- and post-MEP. Secondary outcomes included rates of exacerbations and number of OCS-dependent patients. Results: 106 patients were enrolled in the study: 46 male, median age 58 years. Mean annual cost pre- and post-MEP (cost of biologic excluded) was €3996 and €1,527, respectively. Total savings due to MEP resulted in €2469 (95%CI 1945–2993), 62% due to exacerbations reduction and 33% due to productivity increase. Such savings could fund about 22% of the total cost of MEP for one year. The introduction of MEP induced a clinical benefit by reducing both OCS-dependent patients (OR = 0.12, 95%CI 0.06–0.23) and exacerbation rate (RR = 0.19, 95%CI 0.15–0.24). Conclusions: Patients with severe eosinophilic asthma experienced a clinical benefit in asthma control adding MEP to standard therapy. Biologic therapy can be, partially, funded by the savings produced by patients’ improvement.
AB - Background and aims: Severe asthma is burdened by frequent exacerbations and use of oral corticosteroids (OCS) which worsen patients’ health and increase healthcare spending. Aim of this study was to assess the clinical and economic effect of adding mepolizumab (MEP) for the treatment of these patients. Methods: Patients >18 years old, referred to 8 asthma clinics, starting MEP between May 2017 and December 2018, were enrolled and followed-up for 12 months. Information in the 12 months before mepolizumab were collected retrospectively. The evaluation parameters included: OCS use, number of exacerbations/hospitalizations, concomitant therapies, comorbidity, and annual number of working days lost due to the disease. The primary objective was to compare the annual total cost per patient pre- and post-MEP. Secondary outcomes included rates of exacerbations and number of OCS-dependent patients. Results: 106 patients were enrolled in the study: 46 male, median age 58 years. Mean annual cost pre- and post-MEP (cost of biologic excluded) was €3996 and €1,527, respectively. Total savings due to MEP resulted in €2469 (95%CI 1945–2993), 62% due to exacerbations reduction and 33% due to productivity increase. Such savings could fund about 22% of the total cost of MEP for one year. The introduction of MEP induced a clinical benefit by reducing both OCS-dependent patients (OR = 0.12, 95%CI 0.06–0.23) and exacerbation rate (RR = 0.19, 95%CI 0.15–0.24). Conclusions: Patients with severe eosinophilic asthma experienced a clinical benefit in asthma control adding MEP to standard therapy. Biologic therapy can be, partially, funded by the savings produced by patients’ improvement.
KW - Anti IL-5
KW - Comorbidities
KW - Mepolizumab
KW - OCS
KW - Pharmacoeconomics
KW - Severe asthma
UR - http://www.scopus.com/inward/record.url?scp=85099821012&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099821012&partnerID=8YFLogxK
U2 - 10.1016/j.waojou.2021.100509
DO - 10.1016/j.waojou.2021.100509
M3 - Article
AN - SCOPUS:85099821012
VL - 14
JO - World Allergy Organization Journal
JF - World Allergy Organization Journal
SN - 1939-4551
IS - 2
M1 - 100509
ER -